Letter received from National Medical Products Administration (NMPA) of China regarding Adagloxad Simolenin (OBI-822) Phase III clinical study to be resubmitted after supplementationMay 6, 2019
Announcement of the company’s cash capital increase and base dateJune 14, 2019
- Date of occurrence of the event: Jun 10, 2019
- Reason for the forfeiture of subscription rights by the directors and supervisors: Overall investment strategy and financial planning considerations.
- Names of the directors and supervisor, number of shares forfeited, and their ratio to total subscribable shares:
(1)Director: Yi Tai Investment Co., Ltd.
Waived: 1,674,226 shares, ratio to total subscribable shares: 100%
(2)Director: Sheng Cheng Investment Co., Ltd.
Waived: 0 share, ratio to total subscribable shares: 0%
(3)Independent Director: Jerry Fong, Tony Chang and Taychang Wang do not hold any existing share thus no subscribable share is allotted.
- Name(s) of the specific person(s) and number(s) of shares subscribed: All shares waived by above directors have been distributed to designated persons based on the issued price.
- Any other matters that need to be specified: none